September 28, 2022
Endoceutics Inc. and certain of its affiliates (collectively, the "Endo Group"), a Montréal, Québec-based private pharmaceutical business operating in the fields of women’s health and hormone-sensitive cancer prevention and treatment, obtained CCAA protection on September 28. Despite the Endo Group's significant progress over the years, it has encountered financial difficulties requiring the implementation of a restructuring process, with a view to continuing to develop, produce and market products, including its flagship product Intrarosa. EY was appointed Monitor, and PwC has been engaged as financial advisor to CRG Servicing LLC, the senior secured lender. Counsel is McCarthy's for the Endo Group, Stikeman Elliott for the Monitor and Osler for CRG.
By Dina Milivojevic